Solitek - Solid Technologies

Executive Summary

Solitek Pharma is a Spanish preclinical CRO specializing in solid-state and API development. Founded in 2021, the company leverages over 50 years of cumulative team experience to offer crystallization, solid form screening, characterization, and formulation services. Its target clients include pharmaceutical, biotech, and generic companies, with a focus on accelerating timelines, reducing risks, and ensuring regulatory compliance from late-stage discovery through early clinical development. Solitek's specialized expertise positions it well to capture growing demand for outsourced drug development services. The company remains private and has not disclosed funding or valuation, reflecting its early stage. Upcoming catalysts include potential strategic partnerships, new technology launches, and geographic expansion, which could drive growth and visibility. Given its niche focus and limited public information, Solitek represents a moderate-conviction opportunity with near-term upside if it secures major clients or expands its service offerings.

Upcoming Catalysts (preview)

• Q4 2026Partnership with Major Pharmaceutical Company30% success
• Q3 2026Launch of High-Throughput Screening Platform50% success
• Q1 2027Expansion into European Biotech Hub40% success